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0895-7Introduction: Carotid endarterectomy versus carotid
stenting—A never-ending storyStenosis of the internal carotid artery may be responsible for
10% to 20% of all strokes or transient ischemic attacks. It
should be borne in mind that stroke is the third leading cause
of death and the most common cause of permanent disability
in Western countries. Until the introduction of carotid artery
stenting (CAS), carotid endarterectomy (CEA) was the only
surgical solution to the potential embolic and thrombotic
load of the carotid plaque. During the past few years, medical
therapy has made enormous progress with the introduction
of new drugs and the widespread and more effective control
of vascular risk factors [1]. The choice of treatment between
CEA, CAS, or medical therapy alone for any individual patient
with carotid stenosis remains a controversial issue. However,
a simple complete method to independently stratify the peri-
interventional neurologic outcomes of patients undergoing
CAS is still lacking [2–5]. CEA has been used to treat carotid
disease for more than 50 years. During this period, CEA was
validated by large multicenter randomized clinical trials
(RCTs) [6–10] as an effective method for stroke prevention.
Indications for CEA have been defined, outcomes have mark-
edly improved, and technical aspects have evolved. Despite
the wide acceptance of CEA, the ideal surgical technique to
optimize early outcomes and long-term durability of CEA has
yet to be determined. Consequently, as a practical matter,
most vascular surgeons use a number of technical variations
for CEA in their clinical practice and adapt their preference to
each particular situation. Conventional CEA, performed
through a longitudinal arteriotomy of the internal carotid
artery, followed by primary closure or patch angioplasty, is
the most frequently employed technique. A few prospective
randomized studies have demonstrated that when data on
three principal outcomes (ie, perioperative strokes, early
carotid occlusion, and restenosis 450%) are pooled, the
statistical results strongly favor patch over primary closure
[11–17]. Eversion CEA was initially reported by De Bakey et al
[13], later described by Etheredge [14], and finally adapted by
Raithel and Kasprzak [15] as the simplified version used
today, which involves complete oblique transection of the
internal carotid artery at the bulb. Due to an oblique rather
than a longitudinal arteriotomy, the technique should allow/doi.org/10.1053/j.semvascsurg.2018.03.001
967/$ - see front matter & 2018 Elsevier Inc. All rights reserved.the artery to be less prone to restenosis, particularly when
sutures are placed at the widest part of the artery (ie,
common carotid artery or the base of carotid bulb). Although
it is generally agreed that this technique is safe and effective
[16,17], some concerns remains regarding the possibility that
it is more technically demanding, especially in the case of a
long stenosis plaque or clamping ischemia when a shunt is
needed.
In the last several years, evolution in both stents and
protection devices, as well as in carotid stenting techniques,
resulted in an important reduction in stroke rate in patients
undergoing CAS procedures. Carotid stenting, although it is a
mature technique, regularly applied, and with excellent out-
comes in high-volume centers by expert operators, is strug-
gling to find the consensus of the scientific community. In
fact, the initial enthusiasm for CAS as a valuable and less-
invasive alternative to CEA has been mitigated by the undis-
putable gap in outcomes between the two strategies observed
in RCTs. Inadequate requirements in terms of endovascular
expertise, potentially leading to an increased event rate
related to both insufficient technical skills and inadequate
patient selection, has been proposed as the main reason for
the unfavorable outcomes related to CAS. Despite the fact
that high-quality multicenter registries and high-volume,
single-center experiences have consistently described favor-
able CAS outcomes, the evidence has not been considered
sufficient in the neurologist community to recommend CAS.
Certainly a key issue to limit the periprocedural events to the
lowest possible is to select the appropriate device for the
appropriate patient anatomy and clinical syndrome. Several
studies have shown that the so-called “tailored approach” for
the treatment of carotid disease may offer the best-available
results in term of acute and long-term outcomes. The basic
principle of the tailored approach [18] is the selection of the
appropriate stent and protection device for a specific patient
with a specific lesion and vascular anatomy with the flex-
ibility to use the most appropriate devices and techniques to
manage each individual patient without limitation of an RCT
protocol, such as the restricted use of a particular embolic
protection device and stent system. An important element of
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dependent primarily on the skill of the interventional vascu-
lar specialist, a factor that is substantially more relevant in
the field of CAS than other areas of percutaneous interven-
tion. In fact, Pieniazek et al [19] demonstrated that tailored
CAS is associated with low complication rate and high long-
term efficacy, indicating that operators should be familiar
with the use of different and multiple protection devices and
stent systems in order to be able to use the most appropriate
one. Other authors have written about tailored CAS, focusing
their attention on the kind of stent and embolic protection
device used. Carotid stenting, although it is a mature techni-
que regularly applied with excellent outcomes in high-
volume centers by expert operators, is struggling to find the
consensus of the scientific community. The initial enthu-
siasm for CAS as a valuable and less-invasive alternative to
CEA has been mitigated by the undisputable gap in outcomes
between the two strategies observed in RCTs. But in the last
several years, evolution in both the stents and protection
devices, as well as in carotid stenting techniques, has
resulted in an important reduction in stroke rate in patients
undergoing CAS procedures. In fact, because embolization
through the stent struts is the primary suspected cause of
early postoperative neurologic complications, surgical tech-
nology has focused on the production of a new generation of
stents with a double layer of mesh to reduce the “free area” of
the cells, and new embolic protection devices to reduce the
risk of intraprocedural embolization to the brain. So although
there is still the need for level I evidence from RCTs testing
these new tools, we believe that new materials in the hand of
skilled operators who are able to choose the appropriate
carotid stent and protection device based on the plaque
morphology and patient’s anatomical characteristics may
definitively fill the gap of CAS in comparison to CEA [20–23].
There is great interest in the possibility of learning additional
details regarding the interaction between a carotid plaque
and a stent by optical coherence tomography, considering
that plaque prolapse through the cell stents has been sug-
gested as one of the major causes of post-procedural com-
plications after CAS, and that available intraprocedural
imaging systems (eg, angiography, intravascular ultrasound,
and duplex ultrasound) may not be able to detect these
intravascular microdefects.
The following key issues have been identified:
1. CAS offers a potential alternative to CEA because it is less
invasive, avoids most of the surgical complications, and
prevents future stroke events.
2. Data from RCTs demonstrate significant differences
between CAS and CEA in terms of early neurologic out-
comes (from 0 to 30 days), although mid- and long-term
neurologic results are indistinguishable.
3. Microembolization through the stent struts is considered
the primary suspected cause of early postoperative neuro-
logic complication (ie, nondisabling stroke).
4. Distal protection with filters or occlusive distal balloons
has several restrictions because it requires crossing the
stenosis with the closed devices before protection is
achieved, which increases the risk for embolization.5. Proximal embolic protection devices insulate the brain by
interrupting or reversing the blood flow at the level of the
carotid bifurcation at the time of the procedure. So there is
the crossing of the lesion under protected conditions.
6. The double-layer stents or mesh stents are a new class of
carotid stents that promise to offer higher scaffolding of
carotid plaque in comparison to previous carotid stent
designs, avoiding, or at least limiting, plaque prolapse
through the cell struts.
7. The basic principle of the tailored approach is the selection
of the appropriate stent and protection device for a specific
patient with a specific lesion and vascular anatomy.
With recent stent device approvals, the CAS landscape may
now shift significantly from the individual practice level to
the global market. Examining what brought the field to its
current state is crucial for understanding possible future
changes. It is in that spirit that this issue of Seminars in
Vascular Surgery focuses on revising the status of CAS, high-
lighting the various state-of-the-art treatment modalities
currently available, and the preprocedural and intraproce-
dural strategies that can assist in improving outcomes and
reducing complications.
In the first article of this issue, Alberto Cremonesi et al
describe the tips and tricks for a correct CAS procedure,
starting from basics and including specific anatomical sce-
narios and tailored techniques for safe CAS. Next, Peter
Schneider and Juan Carlos Parodi describe the importance
and proper use of embolic protection devices during CAS,
including specific devices, as well as multiple anatomic and
clinical factors. A number of suggestions about use in various
scenarios and how to improve outcomes are provided. Marc
Bosiers and colleagues report the impact on outcomes of
different types of carotid stenting, underlying how in the
periprocedural phase (Day 0 through Day 30) there is still
some room for improvement of CAS outcomes. To complete
this special issue, Gianmarco de Donato and colleagues
summarize indications and results of an early CAS after
onset of neurologic symptoms, considering the newmaterials
(carotid stents and cerebral protection systems) and
enhanced techniques available.
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